Asia-Pacific Antibody-Drug Conjugates Market (2026-2036)

The growth of this market is mainly driven by the large and rising cancer burden in Asia, the rapid emergence of Asia-originated ADCs and domestic approvals in China, reimbursement expansion for leading ADCs, Japan's leadership in ADC development, and substantial licensing income that funds regional pipelines. However, deep price cuts under reimbursement negotiations, unequal access across lower-income markets, the complexity of high-potency ADC manufacturing, and ADC toxicities, including interstitial lung disease with notable incidence in Asian patients, restrain the growth of this market.

Furthermore, out-licensing of Asian ADC assets to global companies, expansion of ADC contract manufacturing in China and South Korea, bispecific and next-generation ADCs, and broader access in India, Southeast Asia, and Australia are expected to offer growth opportunities for the stakeholders in this market. However, geopolitical pressure on China-origin biotechnology and manufacturing, crowding around HER2 and TROP2, emerging biosimilar competition, and regulatory questions over data generated mainly in Asian populations remain major challenges impacting the growth of this market. Additionally, China's rise as a global ADC innovation hub, the world's first bispecific ADC approval, a strong focus on lung cancer and Asian-prevalent tumors, and topoisomerase I payload dominance are prominent trends in this market.

The Asia-Pacific Antibody-Drug Conjugates (ADC) Market comprises therapeutic agents that link a monoclonal antibody to a potent payload through a chemical linker, sold in Japan, China, South Korea, Australia and New Zealand, India, Taiwan, Singapore, Southeast Asia, and the rest of the region. The market covers ADCs by target, including HER2, TROP2, Nectin-4, hematologic targets, and EGFR, HER3, and other emerging targets; by payload, including topoisomerase I inhibitors, microtubule inhibitors, DNA-damaging agents, and novel payloads; by linker; by format, including monospecific, bispecific, and dual-payload ADCs; and by product origin, distinguishing ADCs developed by multinational companies from those originated in Asia. Market value is measured at manufacturer sales of approved products in the region, consistent with the global ADC market, of which Asia-Pacific accounted for about 16.5% in 2025. The ecosystem includes multinational and Asian pharmaceutical and biotechnology companies, ADC contract development and manufacturing organizations, regulators such as Japan's Pharmaceuticals and Medical Devices Agency and China's National Medical Products Administration, payers including China's National Healthcare Security Administration, and hospitals and cancer centers.

Asia-Pacific is both a major market and a leading source of ADC innovation. Japan's Daiichi Sankyo developed Enhertu and Datroway on its DXd platform, retains exclusive rights to both in Japan, and is responsible for manufacturing and supplying them globally under its collaboration with AstraZeneca. China has become a hub of ADC development: RemeGen's disitamab vedotin, approved in 2021, was followed by Kelun-Biotech's sacituzumab tirumotecan, approved in November 2024 and in lung cancer in March 2025, Hengrui's trastuzumab rezetecan, approved in May 2025, and further domestic approvals, and in June 2026 Sichuan Baili Pharmaceutical and SystImmune's EGFR-HER3 bispecific ADC izalontamab brengitecan, partnered with Bristol Myers Squibb, was reported to have become the world's first approved bispecific ADC.

Demand is underpinned by the region's cancer burden. The International Agency for Research on Cancer estimated about 20 million new cancer cases worldwide in 2022, with Asia accounting for roughly half, and breast, lung, and gastric cancers, all major ADC indications, are among the most common in the region. Reimbursement is expanding access, as illustrated by the acceleration of Enhertu's growth in China following its inclusion in the National Reimbursement Drug List in late 2024. At the same time, Asian ADC developers have secured major licensing agreements with global companies, including Bristol Myers Squibb's USD 800 million upfront payment for SystImmune's bispecific ADC in 2023 and Merck & Co.'s partnership with Kelun-Biotech on sacituzumab tirumotecan.

The market faces important constraints. Reimbursement negotiations in China involve deep price reductions, access remains limited in lower-income markets, interstitial lung disease associated with some ADCs requires careful monitoring, and U.S. legislative scrutiny of certain Chinese biotechnology companies adds uncertainty for China-origin assets and manufacturers. The forecast assumes continued strong growth in Japan, very rapid growth in China driven by domestic ADCs and reimbursement, and gradual access expansion in India and Southeast Asia.